Oltmans Curtis Gale 4
4 · Fulcrum Therapeutics, Inc. · Filed Dec 17, 2025
Insider Transaction Report
Form 4
Oltmans Curtis Gale
Chief Legal Officer
Transactions
- Sale
Common Stock
2025-12-15$12.92/sh−3,452$44,600→ 10,252 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.
- [F2]Includes 10,252 shares that were previously acquired under the Issuer's employee stock purchase plan.